Retrospective study evaluating the performance of risk factors for invasive mold infections in liver transplantation. Issue 1 (12th December 2019)

• Record Type: Journal Article
• Authors: Neyra, Karyna M.; Brizendine, Kyle D.
• Is Part Of: Transplant infectious disease. Volume 22:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-12-12
• Subjects: Aspergillus -- fungal infection -- liver transplant -- mold -- prophylaxis; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.13223
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Background: Mold infections in liver transplant are associated with high mortality. Guidelines recommend prophylaxis targeted against mold based upon risk factors of fulminant hepatic failure, retransplantation, reoperation, and renal replacement therapy post‐transplant. It is not known if these factors identify risk of mold infection at every center. Methods: A retrospective study was conducted of adult liver transplant recipients at a single center from 2010 to 2014. The association between risk factors and invasive mold infection and effect of antifungal prophylaxis were determined. Results: Five hundred thirty‐four liver transplant recipients were identified. The overall incidence of invasive mold infection was 0.9% (N = 5). The incidence in patients with (N = 128) and without (N = 406) risk factors was 0.78% and 0.98%, respectively. Antifungal prophylaxis with mold activity was administered to 23/128 (18%) with risk factors, and none developed infection. No mold‐active prophylaxis was given to 105/128 (82%) with risk factors, and incidence of mold infection was 0.95% (N = 1). Number needed to treat was 105. Conclusions: Traditional risk factors for mold infection in liver transplant performed poorly. These results underscore the importance of transplant center‐specific data to inform adoption of an antifungal prophylactic strategy. Studies are needed to determine alternative risk factors to facilitate appropriate targeting of antifungals.